# PureTech Health PureTech Health is a Clinical-stage biotherapeutics company based in Boston, United States. ## Overview - **Organization type:** Clinical-stage biotherapeutics company - **Headquarters:** Boston, United States - **Region:** North America - **Address:** Boston, MA, United States - **Founded:** 2015 - **Assets under management:** Undisclosed - **Website:** puretechhealth.com - **LinkedIn:** https://www.linkedin.com/company/puretech-health ## Regulatory record - **Reports private funds:** No ## About PureTech Health was founded in 2015 by Daphne Zohar and MIT Institute Professor Robert Langer, structuring itself as a clinical-stage biotherapeutics company that systematically identifies breakthrough academic research and builds standalone drug-development subsidiaries around it. The founding thesis was to bridge the gap between university labs and commercial drug development by pairing deep scientific due diligence with experienced in-house drug developers. The firm listed on the London Stock Exchange in its founding year, giving public investors direct access to venture-creation-stage biotech. PureTech's model diverges from traditional venture capital: it retains majority ownership in its founded entities, controls board seats, and deploys a centralized R&D engine across its portfolio. The firm's strategy centers on creating affiliated companies around specific therapeutic programs — notably in neuroscience, immunology, and the brain-immune-gut axis — then advancing those programs through Phase 2 clinical proof-of-concept before seeking partners or monetization events. Asset classes span direct therapeutics development, platform technologies for drug delivery and digital health, and royalty streams from out-licensed programs. Stage coverage runs from preclinical concept through Phase 2; later-stage assets are typically partnered. Geographic focus is Boston-originated science with transatlantic clinical operations, leveraging the London listing for European investor access. Confirmed portfolio outcomes include Karuna Therapeutics (sold to Bristol Myers Squibb for $14B in December 2023), Gelesis (FDA-cleared weight-management device), and Akili Interactive (FDA-cleared digital therapeutic for ADHD). Team size and total deployment figures are not publicly disclosed. The firm operates from Boston with an additional office in London and a research presence in San Francisco. Publicly known adjacent structures include the PureTech Founded Entities portfolio, each with separate management teams and independent boards but drawing on the parent company's centralized development resources. In September 2024, PureTech received FDA clearance for a pivotal trial of LYT-100 in Idiopathic Pulmonary Fibrosis, advancing its wholly owned deupirfenidone program to registration-stage clinical testing. President Bharatt Chowrira oversees business and strategy functions alongside Zohar's leadership. PureTech's structural differentiator is its public-company architecture applied to venture creation: it operates as a listed entity that originates, incubates, and retains substantial equity in its pipeline subsidiaries. Unlike a traditional venture fund, it does not return capital to LPs on a cycle — it recycles proceeds into new founded entities and can access public equity markets directly for growth capital. This gives the firm permanent capital for long-duration drug development, a model also employed by Roivant Sciences and BridgeBio but pioneered in its current form by PureTech in Europe's biotech ecosystem. Langer's continuous involvement as co-founder provides a proprietary deal-sourcing channel into MIT's research output. ## Sectors - Digital Health - AI/ML - Neuroscience - Immunology - Gastroenterology - Rare Diseases ## Offices - London, United Kingdom ## People - Robert Langer — Co-founder ## Questions ### Who runs investment and portfolio decisions at PureTech Health? Founder and CEO Daphne Zohar leads all strategic and capital allocation decisions, with President Bharatt Chowrira overseeing business operations, strategy, and the Founded Entities portfolio. Co-founder Robert Langer, an MIT Institute Professor and prolific biotech inventor, plays a central role in scientific evaluation and origination but does not hold an executive management position. The firm's board includes directors with public-company and drug-development experience who govern the capital allocation framework. ### How does PureTech Health source its pipeline candidates? PureTech sources primarily through its deep ties to top-tier academic research institutions, particularly MIT and Harvard, leveraging Robert Langer's lab network and the broader Boston biotech ecosystem. The firm evaluates hundreds of early-stage programs annually, looking for novel biological mechanisms with strong preclinical data where its internal drug-development team can materially accelerate translation. The London Stock Exchange listing provides a public-vehicle mechanism for deal origination that academic founders sometimes find more aligned with long-term science goals than traditional venture capital. ### What has PureTech Health's most significant realized return been? Karuna Therapeutics, founded by PureTech in 2011 and taken public in 2019, was acquired by Bristol Myers Squibb for $14 billion in December 2023 — the largest pure-play neuroscience acquisition in recent years. Karuna's lead asset, KarXT (now branded Cobenfy), became the first FDA-approved schizophrenia treatment with a novel mechanism of action in decades. PureTech retained a significant equity stake through the acquisition and continues to hold a royalty interest in the approved product. ### How is PureTech Health related to its Founded Entities like Gelesis and Akili Interactive? PureTech created each Founded Entity as a separate legal company with its own management team, board, and capitalization structure. PureTech maintains majority or significant minority equity ownership in these entities, appoints board representatives, and provides shared access to its drug-development and regulatory expertise. The entities pursue independent financing strategies — including IPOs and partner deals — while PureTech consolidates their performance into its own financial reporting and receives dividends or exit proceeds when stakes are monetized. ### Which therapeutic areas does PureTech Health explicitly focus on? The firm concentrates on neuroscience, immunology, and the brain-immune-gut axis, with active programs in Idiopathic Pulmonary Fibrosis, lymphatic disorders, gastrointestinal indications, and neuropsychiatric conditions. It also maintains exposure to digital therapeutics and medical devices through Founded Entities like Akili Interactive and Gelesis. PureTech has publicly communicated a strategic priority around wholly owned clinical-stage programs alongside the Founded Entities portfolio, effectively operating two parallel pipelines. ## Related profiles - [Keywords Studios](https://altss.com/profile/keywords-studios) - [Exit Ventures](https://altss.com/profile/exit-ventures) --- Last updated: 2026-06-28T01:58:18.802Z Canonical page: https://altss.com/profile/puretech-health-plc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology